NHI-2

NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 14.7 µM. NHI-2 shows selective for LDHA over LDHB (IC50 = 55.8 µM) . NHI-2 is an efficient anti-glycolytic agent. NHI-2 enhances apoptosis, induces cell cycle arrest at S and G2 phases. NHI-2 has a broad spectrum anti-proliferative activity in cancer cells. NHI-2 affects extracellular acidification rate and ATP production. NHI-2 suppresses tumor growth in murine B78 melanoma tumor model[1][2].

Product Specifications

CAS Number

[1269802-97-2]

UNSPSC

12352005

Target

Apoptosis; Lactate Dehydrogenase

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nhi-2.html

Purity

99.10

Solubility

DMSO : 25 mg/mL (ultrasonic; warming)

Smiles

ON1C2=CC(C3=CC=CC=C3)=CC(C(F)(F)F)=C2C=C1C(OC)=O

Molecular Formula

C17H12F3NO3

Molecular Weight

335.28

References & Citations

[1]Granchi C, et al. Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds. Org Biomol Chem. 2013;11 (38) :6588-6596.|[2]Gurel Z, et al. Metabolic modulation of melanoma enhances the therapeutic potential of immune checkpoint inhibitors. Front Oncol. 2024 Oct 1;14:1428802.